CL2017000050A1 - Terapia de combinación para el cáncer - Google Patents

Terapia de combinación para el cáncer

Info

Publication number
CL2017000050A1
CL2017000050A1 CL2017000050A CL2017000050A CL2017000050A1 CL 2017000050 A1 CL2017000050 A1 CL 2017000050A1 CL 2017000050 A CL2017000050 A CL 2017000050A CL 2017000050 A CL2017000050 A CL 2017000050A CL 2017000050 A1 CL2017000050 A1 CL 2017000050A1
Authority
CL
Chile
Prior art keywords
cancer
combination therapy
solvato
antibody
combination
Prior art date
Application number
CL2017000050A
Other languages
English (en)
Inventor
Michael Pourdehnad
Anita Gandhi
Kenichi Takeshita
Rajesh Chopra
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2017000050A1 publication Critical patent/CL2017000050A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>SE PROPORCIONAN EN LA PRESENTE MÉTODOS PARA TRATAR, PREVENIR Y/O MANEJAR LINFOMAS Y LEUCEMIAS ADMINISTRANDO A UN PACIENTE EL COMPUESTO A 3-(5-AMINO-2-METIL-4-OXO-4H-QUINAZOIIN-3-II)-PIPERIDIN-2,6-DIONA), O UNA SAL, SOLVATO O ESTEREOISÓMERO FARMACÉUTICAMENTE ACEPTABLE DEL MISMO EN COMBINACIÓN CON UN ANTICUERPO ANTI-CD20 O IBRUTINIB, O UNA SAL O SOLVATO FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.</p>
CL2017000050A 2014-07-11 2017-01-09 Terapia de combinación para el cáncer CL2017000050A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462023748P 2014-07-11 2014-07-11
US201462033062P 2014-08-04 2014-08-04
US201462033566P 2014-08-05 2014-08-05
US201562149941P 2015-04-20 2015-04-20
US201562156928P 2015-05-05 2015-05-05

Publications (1)

Publication Number Publication Date
CL2017000050A1 true CL2017000050A1 (es) 2017-08-11

Family

ID=53682893

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000050A CL2017000050A1 (es) 2014-07-11 2017-01-09 Terapia de combinación para el cáncer

Country Status (16)

Country Link
US (1) US20170128448A1 (es)
EP (1) EP3166635A1 (es)
JP (1) JP2017521396A (es)
KR (1) KR20170029565A (es)
CN (1) CN107073122A (es)
AU (1) AU2015287694A1 (es)
BR (1) BR112017000556A2 (es)
CA (1) CA2954652A1 (es)
CL (1) CL2017000050A1 (es)
EA (1) EA201790164A1 (es)
HK (1) HK1231381A1 (es)
IL (1) IL249898A0 (es)
MX (1) MX2017000366A (es)
SG (1) SG11201700201UA (es)
WO (1) WO2016007854A1 (es)
ZA (1) ZA201608559B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2420498T (lt) 2006-09-26 2017-10-25 Celgene Corporation 5-pakeistieji chinazolinono dariniai, kaip priešvėžiniai agentai
RS56770B1 (sr) 2011-03-11 2018-04-30 Celgene Corp Čvrste forme 3-(5-amino-2-metil-4-okso-4h-hinazolin-3-il)-piperidin-2,6-diona i njihove farmaceutske smeše i upotrebe
CN104755472A (zh) 2012-09-04 2015-07-01 细胞基因公司 3-(5-氨基-2-甲基-4-氧代喹唑啉-3(4h)-基)哌啶-2,6-二酮的同位素体及其制备方法
WO2017004532A1 (en) 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
EA201891289A1 (ru) * 2015-12-02 2018-11-30 Селджин Корпорейшн Циклическая терапия с применением 3-(5-амино-2-метил-4-оксо-4h-хиназолин-3-ил)пиперидин-2,6-диона
AU2018355145A1 (en) * 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
JP7410877B2 (ja) 2018-05-03 2024-01-10 ジュノー セラピューティクス インコーポレイテッド キメラ抗原受容体（ｃａｒ）ｔ細胞療法とキナーゼ阻害剤の併用療法
CN114828962A (zh) * 2019-10-08 2022-07-29 纪念斯隆凯特琳癌症中心 用于治疗cns淋巴瘤的谷卡匹酶与甲氨蝶呤/利妥昔单抗的联合疗法
US11628172B2 (en) 2019-10-21 2023-04-18 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
KR20220103952A (ko) 2019-10-21 2022-07-25 셀진 코포레이션 (s)-2-(2,6-디옥소피페리딘-3-일)-4-((2-플루오로-4-((3-모르폴리노아제티딘-1-일)메틸)벤질)아미노)이소인돌린-1,3-디온을 포함하는 제약 조성물 및 그의 사용 방법
AU2022263424A1 (en) * 2021-04-21 2023-09-28 Bristol-Myers Squibb Company Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
JP2025503176A (ja) * 2022-01-28 2025-01-30 ジェンマブ エー／エス びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2024108028A1 (en) * 2022-11-16 2024-05-23 Salarius Pharmaceuticals, Inc. Methods of use of deuterium-enriched compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001227851A1 (en) * 2000-01-12 2001-07-24 Emag Technologies L.L.C. Low cost compact omni-directional printed antenna
US7346839B2 (en) * 2003-09-30 2008-03-18 Google Inc. Information retrieval based on historical data
US20060003059A1 (en) * 2004-07-02 2006-01-05 Burt Tabora Combined preparation and apparatus for use with a food blender and method for making preparation
TWI423039B (zh) * 2010-07-23 2014-01-11 Quanta Comp Inc 伺服器系統與其操作方法
EP2683383B1 (en) * 2011-03-11 2017-11-29 Celgene Corporation Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases
MX368286B (es) * 2013-04-17 2019-09-27 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
EP2986318A1 (en) * 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
HK1221168A1 (zh) * 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
EP2991651A1 (en) * 2013-05-03 2016-03-09 Celgene Corporation Methods for treating cancer using combination therapy

Also Published As

Publication number Publication date
US20170128448A1 (en) 2017-05-11
MX2017000366A (es) 2017-04-27
ZA201608559B (en) 2018-04-25
CA2954652A1 (en) 2016-01-14
CN107073122A (zh) 2017-08-18
IL249898A0 (en) 2017-03-30
JP2017521396A (ja) 2017-08-03
EA201790164A1 (ru) 2017-10-31
HK1231381A1 (zh) 2017-12-22
AU2015287694A1 (en) 2017-02-02
SG11201700201UA (en) 2017-02-27
WO2016007854A1 (en) 2016-01-14
KR20170029565A (ko) 2017-03-15
EP3166635A1 (en) 2017-05-17
BR112017000556A2 (pt) 2017-11-07

Similar Documents

Publication Publication Date Title
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
BR112017000556A2 (pt) terapia de combinação para câncer
MX379297B (es) Compuestos alqueno tetrasustituidos y su uso.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
GT201500263A (es) Inhibidores de cdc7
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2017003819A (es) Macrociclos peptidomimeticos y formulaciones de los mismos.
MX378273B (es) Compuestos activos hacia bromodominios.
EA201790398A1 (ru) Способы лечения заболевания печени
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
MX384175B (es) Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva.
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
CL2018001434A1 (es) Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
GB2543709A (en) Pharmaceutical agent
MX2016002307A (es) Tratamiento para el cancer.
AR099416A1 (es) Terapia combinada para la hipertensión resistente
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией